TNXP
$0.57
Tonix Pharm Hld
$.02
3.62%
TNXP
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.11)
Revenue:  $0.00 Mil
Monday
Feb 8
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TNXP reports earnings?
Beat
Meet
Miss

Where is TNXP's stock price going from here?
Up
Flat
Down
Stock chart of TNXP
Analysts
Summary of analysts' recommendations for TNXP
Score
Grade
Pivots
Resistance
$0.61
$0.59
$0.58

$0.57

Support
$0.56
$0.54
$0.53
Tweet
Growth
Description
Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly